

Renaming of Kyowa Hakko Kirin (Singapore) Pte. Ltd.

Tokyo, Japan, 5 September, 2018 – Kyowa Hakko Kirin Co., Ltd. (President and COO: Masashi Miyamoto, “Kyowa Hakko Kirin”) hereby announces that its subsidiary Kyowa Hakko Kirin (Singapore) Pte. Ltd. (Singapore; Managing Director: Chikakuni Kotani) was renamed to Kyowa Kirin Asia Pacific Pte. Ltd. effective August 27, 2018.

Reasons for Renaming

On April 1, 2018, Kyowa Hakko Kirin (Singapore) Pte. Ltd. was given the Asia/Oceania region’s control function, and thus came to control Kyowa Hakko Kirin’s business across the entire Asia/Oceania region excluding Japan, with primary focus on Kyowa Hakko Kirin’s Asian subsidiaries in China, South Korea, Taiwan, Hong Kong, Thailand and Malaysia. Accordingly, Kyowa Hakko Kirin (Singapore) Pte. Ltd. has been renamed so as to clarify its roles and functions.

“In order to leap forward towards the goal of becoming a global specialty pharmaceutical company, we are now striving to expand our Asia and Oceania business,” said Toshifumi Mikayama Ph.D., Director of the Board, Senior Managing Executive Officer of Kyowa Hakko Kirin. “I believe that Kyowa Kirin Asia Pacific Pte. Ltd. plays an important role in contributing to patients and their families in the region.”

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

Overview of Kyowa Kirin Asia Pacific Pte. Ltd.

Established	March 30, 2005
Address	80 Robinson Road #22-01, Singapore 068898, Singapore
Managing Director	Chikakuni Kotani
Paid-in Capital	1 Million SGD
Shareholders	Kyowa Hakko Kirin Co., Ltd. (100%)
Description of business	Control of business in the Asia/Oceania region excluding Japan; sale of pharmaceutical products in Singapore